drugset
drugset / Trial / NCT04324307

Study of Immunotherapy Combined With Chemotherapy in Locally Advanced and Metastatic Pancreatic Cancer

NCT04324307 ↗

Phase 1/2 Unknown 60 enrolled Changhai Hospital
Non-randomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the efficacy of PD-L1/CTLA4 BsAb for the second line treatment and the combination with chemotherapy for the first line treatment in pancreatic cancer

Timeline

Start
2019-11-26
Primary completion
2023-11
Completion
2023-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Calcium Folate Unknown 400 mg/m2 Intravenous
Subject Gemcitabine Small molecule 1000 mg/m2 Intravenous
Subject Irinotecan Small molecule 135 mg/m2 Intravenous
Subject Irinotecan Small molecule 150 mg/m2 Intravenous
Subject Irinotecan Small molecule 180 mg/m2 Intravenous
Subject Oxaliplatin Small molecule 68 mg/m2 Intravenous
Subject Oxaliplatin Small molecule 85 mg/m2 Intravenous
Subject Paclitaxel Small molecule 125 mg/m2 Intravenous
Subject fluorouracil Small molecule 2400 mg/m2 Intravenous

Indications

No indication recorded.